Drugs / CM-101
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06037577 | Mar → May 2019 | metabolic dysfunction-associated steatohepatitis, primary sclerosing cholangitis, systemic sclerosis | ChemomAb Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06044467 | Dec 2018 → Apr 2020 | NAFLD1 | ChemomAb Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06025851 | Jul 2017 → Feb 2018 | — | ChemomAb Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06210945 | Sep 2026 → Jun 2028 | systemic sclerosis | ChemomAb Ltd. | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT05824156 | Feb 2021 → Aug 2022 | metabolic dysfunction-associated steatohepatitis | ChemomAb Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04595825 | Oct 2020 → Jan 2025 | primary sclerosing cholangitis | ChemomAb Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06025851 ↗ |
| Action | Inhibit | “Monoclonal Ab blocking CCL24” NCT05824156 ↗ |
| Modality | Monoclonal antibody | “the anti-human CCL24 monoclonal antibody CM-101” NCT04595825 ↗ |
| Route | Intravenous | “Intravenous Infusion over 60 minutes (±5 minutes)” NCT04595825 ↗ |
| Target | CCL24 | “Monoclonal Ab blocking CCL24” NCT05824156 ↗ |